More Pediatricians Prescribe Spinosad Topical Suspension 0.9%
Spinosad Topical Suspension 0.9% is a proven safe and effective solution for resistant head lice. To date, more than 60% of pediatricians in the US have treated head lice with the compound spinosad.1
Superiority Over Nix®
Spinosad Topical Suspension 0.9% is the only FDA-approved prescription head lice treatment that demonstrated clinical superiority to Nix® (permethrin 1%) in two head-to-head, phase III clinical trials. No nit combing required2.
In two multicenter, randomized, controlled clinical studies under actual-use conditions, significantly more patients using Spinosad Topical Suspension 0.9% were lice-free (no live lice, adults or nymphs) 14 days after the last treatment without nit combing compared to permethrin with combing, 84.6% vs. 44.9% and 86.7% vs. 42.9%, respectively (P<0.001).2
Safety from the Ground Up
The active ingredient in Spinosad Topical Suspension 0.9%, spinosad, derives from a naturally occurring soil microorganism3 that differs from neurotoxic agents such as permethrins and pyrethrins4:

- The compound, spinosad, is not systemically absorbed, even in patients as young as six (6) months of age5
- Spinosad targets lice and nits where they live, never penetrating beyond the stratum corneum, before breaking down through desquamation2
- In a Phase 1 clinical trial, 14 subjects, 4-15 years of age, applied a single topical (scalp) treatment of spinosad 1.8% (twice the active amount of the compound in Spinosad Topical Suspension 0.9%) for 10 minutes. Results demonstrated no systemic absorption of spinosad2
- There is no evidence of neurotoxicity, developmental/reproductive toxicity, immunotoxicity, mutagenicity, or carcinogenicity from spinosad exposure2
Spinosad Topical Suspension 0.9% has also demonstrated similar or lower treatment-related AEs than Nix® (permethrin 1%), the leading OTC medication.6